11 results about "Orally active" patented technology

The present invention relates to the field of pharmaceutical compositions suitable for the oral administration of an active in animals. In particular, the present invention relates to a liquid drug-containing formulation and to the use thereof. The present invention further relates to the use of a liquid formulation aid composition comprising at least one natural oil of herbal origin in a liquid drug-containing formulation for improving the acceptance or voluntary acceptance of drug intake in animal.

The invention discloses an inhibitor acting on a TDP1 target spot and application of the inhibitor. The active ingredient of the inhibitor comprises Lawsone (2-hydroxy-1, 4-naphthoquinone) or SPI-112 (Sodium Sulfonate I-112). The Lawsone is a naphthoquinone compound with oral activity, has antibacterial, antitumor and antioxidant activity, has a molecular formula of C10H6O3, and has a molecular weight of 174.16. The SPI-112 is a protein tyrosine phosphatase inhibitor, the molecular formula of the SPI-112 is C22H17FN4O5S, and the molecular weight of the SPI-112 is 468.46. The inhibitor provided by the invention can be used for effectively reducing CTG trinucleotide repeated amplification in Mykylosing Dystrophy Type 1 (Mykylosing Dystrophy Type 1, DM1) by inhibiting the activity of TDP1 protein, and a new direction is provided for preparing a safe and effective medicine directly aiming at the CTG trinucleotide repeated amplification in DM1.

The invention provides an antibacterial peptide as well as application, a product and a preparation method thereof, and relates to the technical field of biology. The invention screens out a novel antibacterial peptide from kidney beans, which can specifically kill escherichia coli O157: H7 without damaging intestinal flora. By designing protective peptide chains at two ends of an effective sequence, an innovative strategy for keeping oral activity without embedding is established, and the stability and the utilization efficiency are remarkably improved. Meanwhile, a plant-based transgenic expression system is constructed, high-purity production of the antibacterial peptide is realized, and the antibacterial peptide can be directly applied to oral administration.

The disclosure includes compounds in accordance with Formula (I) or Formula (II) wherein R1, R2, and R3 are defined herein and to methods of making those compounds. That disclosure extends 5 to those compounds for the treatment of neoplastic disease, or a method for treating neoplastic disease with these compounds.

The present invention pertains to the fields of biotechnology and neuroscience. More specifically, the invention discloses a novel use of the peptide SEQ ID NO:1 (Asp-Ile-Ile-Ala-Asp-Asp-Glu-Pro-Leu-Thr, or DIIADDEPLT, also known as Pep19) for the preparation of a supplement or drug for sleep modulation. Also disclosed is a method for modulating sleep preferably through oral administration of said peptide or a composition comprising same.

The application discloses an inhibitor acting on a TDP1 target point and application thereof. The active ingredient of the inhibitor comprises Lawsone (2-hydroxy-1, 4-naphthoquinone) or SPI-112. The Lawsone is an orally active naphthoquinone compound, has antibacterial, antitumor and antioxidant activity, and has a molecular formula of C 10 H6O3 and a molecular weight of 174.16. The SPI-112 is a protein tyrosine phosphatase inhibitor, has a molecular formula of C 22 H 17 FN4O5S and a molecular weight of 468.46. The inhibitor provided by the application can effectively reduce CTG trinucleotide repeat expansion in myotonic dystrophy type 1 (DM1) by inhibiting TDP1 protein activity, and provides a new direction for preparing a safe and effective drug directly aiming at the CTG trinucleotide repeat expansion in DM1.

A pharmaceutical composition is described herein, which comprises a therapeutically active agent, an absorption enhancer, and a polymer comprising a plurality of alkaline groups. A concentration of the polymer in the composition is at least 10 weight percent of the total weight of the composition. The absorption enhancer is preferably a substituted or non-substituted fatty acid or a salt thereof. Further described herein are methods of treating a condition treatable by the therapeutically active agent, comprising orally administering the pharmaceutical composition.

A compound of the formulawhere R1, R2, R3, R4, R5, R6a, and R6b are as defined in the specification and claims, or an enantiomer, stereoisomer or diastereoisomer thereof, or a pharmaceutically acceptable salt thereof, and the use thereof in the treatment of diseases, disorders, syndromes and conditions responsive to modulation of a melanocortin receptor.

The invention discloses an application of bacteria in preparation of a synergist for an immune checkpoint inhibitor. The bacteria are active bacteria or inactive whole-cell gut microbiota. By using a monobacterial oral preparation of human endogenous gut microbiota Alistipes combined with an immune checkpoint inhibitor, an anti-tumor immune protective response and an effect of remodeling gut microbiota is generated by stimulation of oral administration of active human commensal gut microbiota or inactive whole-cell human commensal gut microbiota, which significantly enhances an efficacy of the immune checkpoint inhibitor on multiple tumor species, enhances anti-tumor immune function, is conducive to improving the response rate of cancer immunotherapy populations, and has better safety, prolongs overall survival time of cancer patients, expands cancer patient population benefited from cancer immunotherapy (immunotherapy checkpoint inhibitors), provides new combination therapy regimens and therapeutic drugs to treat immune checkpoint inhibitor-refractory tumor patients, and expands the patient benefited from cancer immunotherapy.

The application belongs to the technical field of medicine, and particularly relates to application of trifluperidol in treatment of cerebrovascular diseases. Trifluperidol is a D1 / D2 dopamine receptor antagonist with oral activity and a novel PI3K inhibitor, and trifluperidol has anti-proliferative activity on cancer cells and induces apoptosis. The application discloses trifluperidol for the first time, and no report is found on effective treatment of trifluperidol against ischemic stroke, especially the application creatively proposes that trifluperidol significantly reduces the volume of acute cerebral infarction of a mouse with focal cerebral ischemia, which indicates that trifluperidol can be used for treating ischemic stroke.

An orally active, brain penetrant first-in-class small molecule midkine inhibitor for use in the treatment of triple-negative breast cancer, brain tumors (including glioblastoma, medulloblastoma, and NF1-mutant optic pathway gliomas), ovarian and endometrial cancers, lung cancer, as well as gynecologic non-malignant conditions such as endometriosis, uterine fibroids, and preterm birth, in which tumor cells and / or pathological cells exhibit heightened midkine signaling and express multiple midkine receptors.